Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...112113114115116117118119120121122123124»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Renal cell carcinoma: molecular characterization and evolving treatment paradigms. (Pubmed Central) -  Mar 3, 2017   
    The addition of several new agents effective in metastatic RCC has resulted in improvements in overall survival; however, there are few avenues to durable responses or cure. Ongoing studies as well advances in our understanding of the molecular alterations underlying distinct forms of RCC promise further therapeutic advances and have the potential to alter the current treatment paradigm.
  • ||||||||||  Journal:  EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. (Pubmed Central) -  Feb 24, 2017   
    EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF. E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, PD(L)-1 Biomarker:  Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) -  Jan 26, 2017   
    P2,  N=60, Not yet recruiting, 
    E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients. Initiation date: Jan 2017 --> Apr 2017
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) -  Sep 29, 2016   
    P=N/A,  N=3000, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial initiation date, Metastases:  Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) -  Jul 23, 2016   
    P2,  N=39, Recruiting, 
    Recruiting --> Active, not recruiting | N=210 --> 29 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Trial initiation date, Trial primary completion date:  A Study in Subjects With Recurrent Malignant Glioma (clinicaltrials.gov) -  May 23, 2016   
    P2,  N=151, Completed, 
    Not yet recruiting --> Recruiting Terminated --> Completed | Initiation date: Aug 2010 --> Nov 2010 | Trial primary completion date: Dec 2013 --> Mar 2013